Page 44 - 2019_01-Haematologica-web

D. Qualls et al.
regimen. J Clin Oncol. 1996;14(3):925-934.
77. Rizzieri DA, Johnson JL, Byrd JC, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol. 2014;165(1): 102-111.
78. Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116(18):4283-4290.
79. Cheah CY, Herbert KE, O'Rourke K, et al. A multicentre retrospective comparison of central nervous system prophylaxis strate- gies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014;111(6):1072-1079.
80. Phillips E, Kirkwood A, Lawrie A, et al. Low rates of CNS relapse in high risk DLBCL patients treated with R-CODOX-M and R- IVAC: results from a phase 2 UK NCRI/bloodwise trial. Blood. 2016;128 (22):1855.
81. Herzig RH, Hines JD, Herzig GP, et al. Cerebellar toxicity with high-dose cytosine
arabinoside. J Clin Oncol. 1987;5(6):927-932. 82. Relling MV, Mahmoud HH, Pui CH, et al. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol.
1996;14(2):399-404.
83. Malecek MK, Petrich AM, Rozell S, et al.
Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab. Am J Hematol. 2017;92 (11):1156-1162.
84. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470 (7332):115-119.
85. Davis RE, Ngo VN, Lenz G, et al. Chronic active B cell receptor signaling in diffuse large B cell lymphoma. Nature. 2010;463 (7277):88-92.
86. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;31 (5870):1676-1679.
87. Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833-843.e5.
88. Houillier C, Choquet S, Touitou V, et al. Lenalidomide monotherapy as salvage treat- ment for recurrent primary CNS lymphoma. Neurology. 2015;84(3):325-326.
89. Ayed AO, Chiappella A, Pederson L, et al. CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 stud- ies. Blood Cancer J. 2018;8(7):63.
90. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311-319.
91. Kiyasu J, Miyoshi H, Hirata A, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126(19):2193-2201.
92. Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving pro- grammed death ligands are recurrent in pri- mary mediastinal large B-cell lymphoma. Blood. 2014;123(13):2062-2065.
93. Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071-3073.
34
haematologica | 2019; 104(1)